US › Healthcare

Gossamer Bio Inc (GOSS)

US · Healthcare · Biotechnology

$11.94+8.94%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$9.2M

Revenue YoY

-19.6%

Net profit

$16.9M

EPS

$-0.20

EPS estimate

$-0.10

Net margin

182.9%

EPS came in at -0.20 against a street estimate of -0.10 — a miss of 100.0%.

Key statistics

Market cap

$65.6M

Forward P/E

0.0

P/B

2.66

Book value

$-0.19

EPS (TTM)

$-0.66

52-week high

$309.60

52-week low

$9.12

50-day MA

$0.17

200-day MA

$1.06

Beta

2.00

Analyst view

Analysts rate Gossamer Bio Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $132.48.

Shareholding

Insiders

1.52%

Institutions

85.86%

Largest institutional holders

Fund	Stake
D. E. Shaw & Co LP	8.38%
Worth Venture Partners, LLC	5.12%
Kalehua Capital Management LLC	3.62%
BlackRock Inc	3.44%
GSA Capital Partners LLP	3.07%
AQR Capital Management LLC	2.07%
Vanguard Capital Management, LLC	1.92%
ARCH VENTURE CORP	1.65%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gossamer Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.